Background: Biological systems integrate metabolic, energy and signaling networks, by maintaining dense webs of control circuits and multiple adaptors common to two or more interfacing networks. My lecture will concentrate on systemic defects in signaling networks involved in malignant cell proliferation and migration. As a starting point, I will argue that primordial signaling pathways have been replaced in the course of metazoan evolution by layered signaling networks. The driving process behind this transformation has been whole genome duplications, which established modularity, an essential feature of biological robustness. Other features of robustness include redundancy
Background: Biological systems integrate metabolic, energy and signaling networks, by maintaining dense webs of control circuits and multiple adaptors common to two or more interfacing networks. My lecture will concentrate on systemic defects in signaling networks involved in malignant cell proliferation and migration. As a starting point, I will argue that primordial signaling pathways have been replaced in the course of metazoan evolution by layered signaling networks. The driving process behind this transformation has been whole genome duplications, which established modularity, an essential feature of biological robustness. Other features of robustness include redundancy and systems control, primarily feedback and feed-forward loops that maintain homeostasis and determine the outcome of network activation. Unlike linear pathways, networks can be trained to overcome perturbations, and their control wirings are much more sophisticated. These differences are relevant to pharmacological attempts to intercept signaling networks, as well as to the excessive reliance of oncogenic networks on 1-2 essential hubs ('oncogene addiction'). Using the epidermal growth factor receptor (EGFR) and its kin, a kinase called HER2/ERBB2, I will exemplify defects in system control and feedback regulation, and highlight some of the currently approved drugs that target the EGFR-HER2 axis. Along with illuminating the rationale of combination therapies, the lecture will focus on acquired (secondary) resistance to molecular targeted therapies, as an example of the remarkable adaptive capacity of signaling networks.
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